Science News
from research organizations

Prostate screening: Combining MRI with conventional prostate surveillance effective, study suggests

Date:
March 23, 2015
Source:
European Association of Urology
Summary:
Initial results from a randomized screening trial indicates that using MRI (Magnetic Resonance Imaging) alongside conventional prostate cancer screening seems to offer improved cancer detection and can help avoid unnecessary biopsies.
Share:
FULL STORY

Initial results from the Göteborg randomised screening trial indicates that using MRI (Magnetic Resonance Imaging) alongside conventional prostate cancer screening seems to offer improved cancer detection and can help avoid unnecessary biopsies.

Prostate cancer is the third most common male cancer in Europe, accounting for over 92,000 deaths in 2012 (9% of male deaths). Screening for prostate cancer is a controversial issue, with until recently, little clear evidence that existing screening procedures, using PSA (to be followed by biopsies), were effective. In general, either the screening has tended to miss many cancers, or to give false positives, meaning that many men are subject to invasive testing and perhaps treatment which was just not necessary.

The Göteborg Trial is the Swedish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC), which is the largest randomized prostate cancer screening trial in the world. In 2014 results from this trial showed a significant mortality reduction with prostate-specific antigen (PSA) screening for men aged 55-69 years of age. Now new work, presented at the European Association of Urology Conference in Madrid, shows that using MRI may further improve the accuracy of prostate cancer screening. 

A group of Swedish researchers, led by Prof Jonas Hugosson took 384 patients attending the Göteborg trial, and asked 124 of these to go for an MRI prior to having a biopsy. Those with a suspicious MRI, or with a PSA > 3 ng/ml, were referred for biopsy. These biopsies were both standard samples, where 10 tissue samples are taken at random from the prostate, and targeted biopsies, where samples were taken from the suspicious areas seen on the MRI.

The results showed that the combining PSA and MRI, followed by MRI-targeted biopsy only in men with suspicious MRI gave better prostate cancer detection (as confirmed by biopsy) than PSA scores alone followed by standard random biopsy (7.0% versus 5.2%). The results also showed that more significant (potentially aggressive) cancers were detected with PSA + MRI combined compared with using PSA as a stand-alone test in screening.

Analysing the results, the Göteborg group suggests that this combination may point to a strategy to maximise success in prostate cancer screening.

According to researcher, Dr Anna Grenabo-Bergdahl: "From these initial results it looks like we can combine PSA levels with MRI scans to give more accurate screening results. This strategy would allow us to take men with lower PSA scores, and give them MRI scans, to confirm whether or not a biopsy is absolutely necessary. Another benefit is that the MRI helps us locate the suspect area, meaning that if we have to do a confirmatory biopsy, we have a much better idea of where the problem might be. This avoids patient stress, and means we are less likely to miss cancers."

She continued: "These results from the pilot study are very encouraging, but now they need to be confirmed. We are starting a trial of 40,000 patients in the Göteborg area. If we can replicate the results from our pilot study this may lead to a paradigm shift in future screening and fundamentally change the way we handle early detection of prostate cancer."

Commenting, European Association of Urology Treasurer, Professor Manfred Wirth (Dresden) said: "These initial results, which confirm some of the work we have been doing here in Dresden, show that MRI-targeted biopsy has the potential to change how we diagnose prostate cancer. There are still real issues to address; for example MRI is currently not cost-effective to use in routine screening. As the authors say, we are still some way off considering using MRI for routine screening, and we need a bigger study to validate these results. But this is a positive proof of principle, and certainly merits more investigation."


Story Source:

Materials provided by European Association of Urology. Note: Content may be edited for style and length.


Cite This Page:

European Association of Urology. "Prostate screening: Combining MRI with conventional prostate surveillance effective, study suggests." ScienceDaily. ScienceDaily, 23 March 2015. <www.sciencedaily.com/releases/2015/03/150323075759.htm>.
European Association of Urology. (2015, March 23). Prostate screening: Combining MRI with conventional prostate surveillance effective, study suggests. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/03/150323075759.htm
European Association of Urology. "Prostate screening: Combining MRI with conventional prostate surveillance effective, study suggests." ScienceDaily. www.sciencedaily.com/releases/2015/03/150323075759.htm (accessed May 23, 2017).

RELATED STORIES